BioTime awarded 14 new patents

BioTime (NYSEMKT:BTX) reports that it was been awarded 14 new patents in Australia, Canada, China, Japan and the U.S. The company now has over 600 existing patents and patent applications in the field of pluripotent stem cell technology.

Comments (1)
  • dennisg57
    , contributor
    Comment (1) | Send Message
    Great, but when are they going to start monetizing these 600 patents for shareholders. It is time they started giving us stockholders a ROI.
    15 Jul 2014, 10:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs